Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

468.08 -5.61 (-1.18%)
Streaming Delayed Price Updated: 3:35 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Evergreen business models make it easier to hold for the long run. 
Via The Motley Fool
13 Analysts Have This To Say About Vertex Pharmaceuticals
Via Benzinga
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having... 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks. 
Via The Motley Fool
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Why NASDAQ:VRTX Stands Out as a Quality Stock. 
Via Chartmill
2 Healthcare Stocks to Buy Hand Over Fist in June
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
This Is What Whales Are Betting On Vertex Pharmaceuticals
Via Benzinga
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
NASDAQ:VRTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
2 Biotech Stocks to Buy in May
You could buy these in any month, really. 
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
3 No-Brainer Stocks to Buy in June
Now is the time to invest in these great stocks. 
Via The Motley Fool
5 Top Stocks to Buy in June
This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... 
Via Talk Markets
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high. 
Via Investor's Business Daily
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
Got $500? 3 Pharma Stocks to Buy and Hold Forever
These players might even beat the market when the conditions are right. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the growing biotech company have doubled in three years. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
SLB, First Solar And 2 Other Stocks Insiders Are Selling
Via Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. 
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.